BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The aim of the present study is to investigate the safety of BI 10773 treatment in patients
with Type 2 Diabetes Mellitus and high cardiovascular risk.